Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibodies directed to angiopoietin-2 and uses thereof

An angiopoietin and antibody technology, applied in the field of hybridoma or other cell lines, can solve problems other than anticancer therapy

Active Publication Date: 2008-02-20
ASTRAZENECA AB
View PDF69 Cites 27 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This pro-angiogenic effect from angiopoietin-1 inhibition suggests that anti-angiopoietin-1 therapy is not an effective anticancer therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies directed to angiopoietin-2 and uses thereof
  • Antibodies directed to angiopoietin-2 and uses thereof
  • Antibodies directed to angiopoietin-2 and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0057] The embodiments of the invention described herein relate to monoclonal antibodies that bind to Ang-2. In some embodiments, the antibody binds Ang-2 and inhibits the binding of Ang-2 to its receptor Tie2. Other embodiments of the present invention include fully human anti-Ang-2 antibodies, and antibody preparations with therapeutic utility. Such anti-Ang-2 antibody preparations preferably have the desired therapeutic properties, including strong binding affinity to Ang-2, the ability to neutralize Ang-2 in vitro, and the ability to inhibit Ang-2 induced angiogenesis in vivo ability.

[0058] One embodiment of the invention includes antibodies that bind and neutralize Ang-2 but not Ang-1. In one embodiment, the antibody binds to both Ang-2 and Ang-1, but only neutralizes Ang-2. In another embodiment, the antibody binds to both Ang-2 and Ang-1, and neutralizes the binding of Ang-1 and Ang-2 to Tie2.

[0059] Embodiments of the invention also include isolated binding fragments ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and / or complementary determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobin molecules and monoclonal antibodies.

Description

[0001] This application claims priority to the U.S. Provisional Application Serial No. 60 / 638,354 filed on December 21, 2004 and the U.S. Provisional Application Serial No. 60 / 711,289 filed on August 25, 2005, which are incorporated herein by reference. Invention field [0002] The present invention relates to monoclonal antibodies against Angiopoietin-2 (Ang-2) and applications of these antibodies. More particularly, the present invention relates to fully human monoclonal antibodies against Ang-2 and the applications of these antibodies. The invention also relates to hybridomas or other cell lines expressing these antibodies. The antibodies can be used to diagnose and treat diseases related to the activity and / or overproduction of Ang-2. Background of the invention [0003] Angiogenesis is the process of forming new capillaries from existing blood vessels. It is a basic component of embryogenesis, normal physiological growth, repair and tumor expansion. Although there are many fa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/22C07K16/28C12N15/13C12N15/85
CPCC07K16/22C07K2317/92A61K39/39558C07K2317/21C07K14/515A61K2039/505C07K2317/56C07K2316/96C07K2317/76A61P1/00A61P1/16A61P1/18A61P11/00A61P13/00A61P13/12A61P17/00A61P35/00A61P43/00A61P5/00A61P9/00C07K16/28C12N15/11C12N15/85
Inventor L·L·格林Q·周B·A·基特X·杨S·C·埃默里D·C·布莱基
Owner ASTRAZENECA AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com